A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice

doi:10.1084/jem.184.3.1149

This Article

	Full Text (PDF, 3849K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Peng, S. L.
	Articles by Craft, J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Peng, S. L.
	Articles by Craft, J.


Social Bookmarking

	What's this?

ARTICLES

A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice

SL Peng, ME Robert, AC Hayday and J Craft
Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.

Fas (CD95) and its ligand are central regulatory molecules in hematopoietic cells. Previous studies have suggested a role for Fas in the regulation of tumor progression, but Fas has not yet been conclusively identified as a tumor suppressor. Fas-deficient individuals lack malignant tumors, perhaps because of regulation by T cells. To investigate such a possibility, mice deficient in both T cells and Fas were generated, and they were found to develop severe B cell dysregulation characterized by malignant, lethal B cell lymphoma. Lymphoma arose from a monoclonal B220+CD19-CD5-CD23- B cell secreting immunoglobulin M, kappa rheumatoid factor. In contrast, animals containing alpha beta T cells, gamma delta T cells, and/or functional Fas suppressed the development of lymphoma. These data indicate that Fas functions as a tumor suppressor, and identifies roles for both alpha beta T cells and gamma delta T cells in Fas-independent tumor regulation.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Imtiyaz, H. Z., Zhou, X., Zhang, H., Chen, D., Hu, T., Zhang, J. (2009). The Death Domain of FADD Is Essential for Embryogenesis, Lymphocyte Development, and Proliferation. J. Biol. Chem. 284: 9917-9926 [Abstract] [Full Text]
Lin, L., Brody, S. L., Peng, S. L. (2005). Restraint of B Cell Activation by Foxj1-Mediated Antagonism of NF-{kappa}B and IL-6. J. Immunol. 175: 951-958 [Abstract] [Full Text]
Strater, J, Hinz, U, Hasel, C, Bhanot, U, Mechtersheimer, G, Lehnert, T, Moller, P (2005). Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 54: 661-665 [Abstract] [Full Text]
Zhang, J. Q., Okumura, C., McCarty, T., Shin, M. S., Mukhopadhyay, P., Hori, M., Torrey, T. A., Naghashfar, Z., Zhou, J. X., Lee, C. H., Roopenian, D. C., Morse, H. C. III, Davidson, W. F. (2004). Evidence for Selective Transformation of Autoreactive Immature Plasma Cells in Mice Deficient in Fasl. JEM 200: 1467-1478 [Abstract] [Full Text]
Street, S. E.A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., Smyth, M. J. (2004). Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and {gamma}{delta} T Cells. JEM 199: 879-884 [Abstract] [Full Text]
Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., Tigelaar, R. E., Hayday, A. C. (2003). The Distinct Contributions of Murine T Cell Receptor (TCR){gamma}{delta}+ and TCR{alpha}{beta}+ T Cells to Different Stages of Chemically Induced Skin Cancer. JEM 198: 747-755 [Abstract] [Full Text]
Greil, R., Anether, G., Johrer, K., Tinhofer, I. (2003). Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J. Leukoc. Biol. 74: 311-330 [Abstract] [Full Text]
Embree-Ku, M., Boekelheide, K. (2002). FasL Deficiency Enhances the Development of Tumors in p53+/- Mice. Toxicol Pathol 30: 705-713 [Abstract]
Engel, I., Murre, C. (2002). Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice. Proc. Natl. Acad. Sci. USA 99: 11322-11327 [Abstract] [Full Text]
Straus, S. E., Jaffe, E. S., Puck, J. M., Dale, J. K., Elkon, K. B., Rosen-Wolff, A., Peters, A. M. J., Sneller, M. C., Hallahan, C. W., Wang, J., Fischer, R. E., Jackson, C. M., Lin, A. Y., Baumler, C., Siegert, E., Marx, A., Vaishnaw, A. K., Grodzicky, T., Fleisher, T. A., Lenardo, M. J. (2001). The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98: 194-200 [Abstract] [Full Text]
Lafleur, E. A., Jia, S.-F., Worth, L. L., Zhou, Z., Owen-Schaub, L. B., Kleinerman, E. S. (2001). Interleukin (IL)-12 and IL-12 Gene Transfer Up-Regulate Fas Expression in Human Osteosarcoma and Breast Cancer Cells. Cancer Res. 61: 4066-4071 [Abstract] [Full Text]
Sun, S.-Y., Yue, P., Hong, W. K., Lotan, R. (2000). Induction of Fas Expression and Augmentation of Fas/Fas Ligand-mediated Apoptosis by the Synthetic Retinoid CD437 in Human Lung Cancer Cells. Cancer Res. 60: 6537-6543 [Abstract] [Full Text]
Pinkoski, M. J., Brunner, T., Green, D. R., Lin, T. (2000). Fas and Fas ligand in gut and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G354-G366 [Abstract] [Full Text]
Kazama, H., Yonehara, S. (2000). Oncogenic K-Ras and Basic Fibroblast Growth Factor Prevent FAS-Mediated Apoptosis in Fibroblasts through Activation of Mitogen-Activated Protein Kinase. JCB 148: 557-566 [Abstract] [Full Text]
Newton, K., Strasser, A. (2000). Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling: Implications for Cancer Therapy. JEM 191: 195-200 [Abstract] [Full Text]
Ueno, T., Toi, M., Tominaga, T. (1999). Circulating Soluble Fas Concentration in Breast Cancer Patients. Clin. Cancer Res. 5: 3529-3533 [Abstract] [Full Text]
Maeda, T., Yamada, Y., Moriuchi, R., Sugahara, K., Tsuruda, K., Joh, T., Atogami, S., Tsukasaki, K., Tomonaga, M., Kamihira, S. (1999). Fas Gene Mutation in the Progression of Adult T Cell Leukemia. JEM 189: 1063-1071 [Abstract] [Full Text]
Owen-Schaub, L. B., van Golen, K. L., Hill, L. L., Price, J. E. (1998). Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis. JEM 188: 1717-1723 [Abstract] [Full Text]
Davidson, W. F., Giese, T., Fredrickson, T. N. (1998). Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas-Fas Ligand Interactions. JEM 187: 1825-1838 [Abstract] [Full Text]
Beltinger, C., Kurz, E., Bohler, T., Schrappe, M., Ludwig, W.-D., Debatin, K.-M. (1998). CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood 91: 3943-3951 [Abstract] [Full Text]
Plumas, J., Jacob, M.-C., Chaperot, L., Molens, J.-P., Sotto, J.-J., Bensa, J.-C. (1998). Tumor B Cells From Non-Hodgkin's Lymphoma Are Resistant to CD95 (Fas/Apo-1)-Mediated Apoptosis. Blood 91: 2875-2885 [Abstract] [Full Text]
Peng, S. L., Moslehi, J., Robert, M. E., Craft, J. (1998). Perforin Protects Against Autoimmunity in Lupus-Prone Mice. J. Immunol. 160: 652-660 [Abstract] [Full Text]